相关实验视频

Updated: Jun 11, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

TAM-tastic:从抗性到性在癌症中

Jie Ting Low¹, Ping-Chih Ho¹, Mai Matsushita¹

¹Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.

Trends in pharmacological sciences

|October 2, 2024

概括

用帕克利塔塞尔 (PTX) 阻断瘤相关巨细胞的TIM3或VISTA,可以克服癌症免疫疗法耐药性. 这种方法重编程TAM以向癌细胞,提供了一种新的治疗策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

与瘤相关的巨细胞 (TAMs) 可以阻碍癌症免疫治疗的有效性.
在TAMs上,T细胞免疫球蛋白和含有3 (TIM3) 和V-域免疫球蛋白抑制T细胞激活 (VISTA) 的粘素域的同时表达与免疫疗法耐药性有关.
具有有限的T细胞透的瘤微环境 (TME) 加剧了这一挑战.

研究的目的:

为了研究一种克服癌症免疫疗法耐药性的新疗法策略.
探索针对TAM的TIM3和VISTA的潜力.
评估TIM3/VISTA与帕克利塔塞尔 (PTX) 联合阻断在TAM重编程中的有效性.

主要方法:

在临床前癌症模型中利用IL-4支持的TAM.
使用帕克利塔塞尔 (PTX) 结合TIM3或VISTA的阻断.
评估了TAMs的重编程及其抗癌活性.

主要成果:

在IL-4支持的TAM上阻断TIM3或VISTA,当与PTX相结合时,显示出显著的抗癌作用.
综合治疗重编程了TAMs,使其能够积极攻击癌细胞.
这一策略在克服TME阻力机制方面显示出前途.

结论:

针对TAM的TIM3和VISTA是增强癌症免疫疗法的潜在新治疗途径.
免疫检查点封锁和化疗的结合提供了一个有希望的策略来克服治疗耐药性.
重编程TAM可能是改善挑战性癌症类型患者治疗结果的关键.

关键词:

癌症免疫疗法免疫疗法免疫性细胞死亡免疫性细胞死亡免疫抵抗性免疫抵抗性免疫抵抗性与瘤相关的巨细胞.

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...